News

Novartis cannot block generic version of Entresto, judge rules
A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...
Novartis AG (NVS) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic Initiatives ...
Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...
Drug Store News21h
U.S. federal judge rejects Novartis’ efforts to block MSN's generic Entresto
Novartis could soon face generic competition for Entresto after judge's ruling.
Novartis loses bid to block US Entresto generic through 2026
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...
Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)
The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Fierce Pharma21h
Novartis’ Pluvicto finally picks up speed, delivers another trial win in early prostate cancer
Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...
BioSpace23h
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...
NDTV Profit on MSN4d
Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...